First Quadrant’s MacroGenics MGNX Stock Holding History

First Quadrant’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,300	Closed	-$216K	–	532
2021 Q3	$216K	Hold	10,300	–	–	0.03%	335
2021 Q2	$277K	Hold	10,300	–	–	0.03%	304
2021 Q1	$328K	Buy	+10,300	New	+$250K	0.03%	315

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

First Quadrant's MGNX Position: Q4 2021 in Review

First Quadrant sold out of MacroGenics (MGNX) in Q4 2021, closing a stake of 10,300 shares — an estimated $216K sold.

First Quadrant first reported a position in MGNX in Q1 2021 and held it in 3 quarters. The position peaked at $328K in Q1 2021. 156 funds tracked by Wall St. Rank hold MGNX as of Q4 2021.

First Quadrant reported no remaining MacroGenics position as of Q4 2021 after selling out during the quarter.
First Quadrant sold 10,300 MacroGenics shares in Q4 2021, an estimated $216K.
First Quadrant first reported a position in MacroGenics in Q1 2021 and held it in 3 quarters.
First Quadrant's MacroGenics position peaked at $328K in Q1 2021.
156 funds tracked by Wall St. Rank held MacroGenics as of Q4 2021.

Based on First Quadrant's 13F filing for Q4 2021, filed 27 Jan 2022.